Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia.

"CONFLICT OF INTEREST DISCLOSURES Gesine Bug reports a grant (paid to her institution) from Novartis; honoraria from Jazz Pharmaceuticals (paid to her institution), Celgene, and Gilead; support for attending meetings and/or travel from Jazz Pharmaceuticals, Gilead, and Neovii; and payment for participation on an advisory board from Novartis, Pfizer, Eurocept, Gilead, and Celgene. Charles Craddock reports grants from Celgene, Bloodwise, Cancer Research UK, and Cure Leukemia; and honoraria from Celgene, Daichi‐Sankyo, Novartis, and Pfizer. Justin Loke reports payment or honoraria from Pfizer, Janssen and Amgen; and travel support from Novartis and Daichi‐Sankyo. The other authors made no disclosures."

"Bloodwise 10.13039/501100007903; Cure Leukemia; Cancer Research UK 10.13039/501100000289"